A detailed history of Bank Of America Corp transactions in Nektar Therapeutics stock. As of the latest transaction made, Bank Of America Corp holds 218,263 shares of NKTR stock, worth $202,984. This represents 0.0% of its overall portfolio holdings.

Number of Shares
218,263
Previous 182,036 19.9%
Holding current value
$202,984
Previous $225,000 25.78%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.11 - $1.48 $40,211 - $53,615
36,227 Added 19.9%
218,263 $283,000
Q2 2024

Aug 14, 2024

BUY
$0.9 - $1.83 $125,811 - $255,815
139,790 Added 330.9%
182,036 $225,000
Q1 2024

May 15, 2024

SELL
$0.49 - $0.96 $57,874 - $113,386
-118,111 Reduced 73.66%
42,246 $39,000
Q4 2023

Feb 14, 2024

SELL
$0.42 - $0.57 $7,981 - $10,831
-19,003 Reduced 10.59%
160,357 $89,000
Q2 2023

Aug 14, 2023

SELL
$0.53 - $1.03 $41,456 - $80,565
-78,219 Reduced 30.37%
179,360 $104,000
Q1 2023

May 12, 2023

BUY
$0.64 - $3.15 $38,597 - $189,973
60,309 Added 30.57%
257,579 $180,000
Q4 2022

Feb 10, 2023

SELL
$2.03 - $4.28 $360,318 - $759,687
-177,497 Reduced 47.36%
197,270 $445,000
Q3 2022

Nov 14, 2022

BUY
$3.04 - $5.14 $153,726 - $259,919
50,568 Added 15.6%
374,767 $1.2 Million
Q2 2022

Aug 12, 2022

BUY
$3.17 - $6.17 $824,028 - $1.6 Million
259,946 Added 404.57%
324,199 $1.23 Million
Q1 2022

May 16, 2022

SELL
$4.16 - $13.72 $242,403 - $799,464
-58,270 Reduced 47.56%
64,253 $346,000
Q4 2021

Feb 08, 2022

SELL
$10.83 - $18.41 $560,463 - $952,735
-51,751 Reduced 29.7%
122,523 $1.66 Million
Q3 2021

Nov 15, 2021

BUY
$13.07 - $18.84 $567,159 - $817,542
43,394 Added 33.16%
174,274 $3.13 Million
Q2 2021

Sep 13, 2021

BUY
$16.52 - $20.4 $2.16 Million - $2.67 Million
130,880 New
130,880 $2.25 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.